Real‐world effectiveness and safety of <scp>RC48‐ADC</scp> alone or in combination with <scp>PD</scp>‐1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study
Cancer medicine